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Background. The Infectious Diseases Society of America (IDSA) guidelines for the management of histoplasmosis were last
revised 15 years ago. Since those guidelines were compiled, new antifungal treatment options have been developed.
Furthermore, the ongoing development of immunomodulatory therapies has increased the population at increased risk to
develop histoplasmosis.
Methods. An electronic survey about the management practices of histoplasmosis was distributed to the adult infectious disease
(ID) physician members of the IDSA’s Emerging Infections Network.
Results. The survey response rate was 37% (551/1477). Only 46% (253/551) of respondents reported seeing patients with
histoplasmosis. Regions considered endemic had 82% (158/193) of physicians report seeing patients with histoplasmosis
compared to 27% (95/358) of physicians in regions not classically considered endemic (P < 0.001). Most ID physicians follow
IDSA treatment guidelines recommending itraconazole for acute pulmonary (189/253 [75%]), mild-moderate disseminated
(189/253 [75%]), and as step-down therapy for severe disseminated histoplasmosis with (232/253 [92%]) and without (145/253
[57%]) central nervous system involvement. There were no consensus recommendations observed for survey questions
regarding immunocompromised patients.
Conclusions. Though there are increased reports of histoplasmosis diagnoses outside regions classically considered endemic, a
majority of ID physicians reported not seeing patients with histoplasmosis. Most respondents reported adherence to IDSA
guidelines recommending itraconazole in each clinical situation. New histoplasmosis guidelines need to reflect the growing need
for updated general guidance, particularly for immunocompromised populations.
Keywords. amphotericin; clinical practice; Histoplasma capsulatum; histoplasmosis; itraconazole.
Histoplasmosis is caused by the dimorphic fungal pathogen
Histoplasma capsulatum. It exists as a mold in the environment,
converting to the yeast form upon infection of a human host.
Infection usually occurs by inhalation of environmental spores
and can occur in both immunocompetent and immunocom
promised hosts [1]. Given this mode of transmission, respirato
ry infection is the most common manifestation. The spectrum
of disease ranges from asymptomatic to severe, life-threatening
disseminated infection. The most severe manifestations occur
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in immunocompromised individuals, with mortality ranging
from 7% to 44% [2–5].
A timely diagnosis requires high clinical suspicion by clini
cians. This suspicion is frequently reliant on a patient exposure
to an area considered to be endemic for Histoplasma—the Ohio
and Mississippi river valleys. Despite ample evidence of its
presence globally, Histoplasma is still considered by many to
be predominately endemic to specific regions of North
America [6, 7]. This perception can result in clinicians failing
to consider histoplasmosis on a differential diagnosis, contrib
uting to delayed diagnosis and poor outcomes.
The Infectious Diseases Society of America (IDSA) last up
dated clinical guidelines for the management of histoplasmosis
in 2007, using literature from 1 January 1999 through 31 June
2006 [8]. Since the release of the guidelines, new treatment op
tions have been developed. Posaconazole was approved by the
United States (US) Food and Drug Administration shortly be
fore the release of the 2007 guidelines and isavuconazole was
approved in 2015. Both maintain in vitro activity against
Histoplasma even in the setting of fluconazole resistance
[9, 10], though there are limited clinical data to support their
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METHODS

An electronic survey was distributed among the physician mem
bers of the IDSA Emerging Infections Network (EIN) who prac
tice adult ID. EIN is an IDSA and Centers for Disease Control
and Prevention (CDC)–supported provider-based surveillance
network [20]. EIN has a well-established history of leveraging
surveys of its membership to provide key insights into the prac
tice of ID. Its membership represents approximately 20% of ID
physicians in the US. The survey consisted of 11 questions and 1
additional space to provide free-text commentary. Five ques
tions were case-based scenarios and the remainder referred to
specific aspects of histoplasmosis management. An opt-out re
sponse was provided for physicians who do not see patients
with histoplasmosis. The US Census Bureau geographic re
gion/division [21], years of experience, and clinical practice
characteristics for each EIN member were available from an ex
isting EIN member database. The survey was distributed on 16
November 2021. Two reminder invitations were sent out for
nonresponders prior to closure of the survey on 1 January 2022.
Each of the clinical scenarios was designed to suggest a spe
cific manifestation of histoplasmosis using definitions from the
current guidelines [8]. Each case also sought to reflect the
often-ambiguous presentation of histoplasmosis. During devel
opment of the survey, the diagnosis in each case was agreed
upon by the authors, who are ID physicians practicing in
Histoplasma-endemic regions, regularly see patients with histo
plasmosis, and have a history of histoplasmosis clinical re
search. The remainder of the questions were generated to
inquire about real-world practice patterns regarding specific as
pects of histoplasmosis management where there are few data
to guide clinical decisions. The full survey is available in the
Supplementary Materials.
The following US Census Bureau divisions are defined as en
demic: East North Central, West North Central, East South
Central, and West South Central.
2 • OFID • Mazi et al

RESULTS

The survey was distributed to 1477 EIN physician members
with an adult ID practice who have previously responded to
an EIN survey of whom 37% (551/1477) responded; 46%
(253/551) of the respondents reported seeing patients diag
nosed with histoplasmosis. Years of ID experience was signifi
cantly different between respondents and nonrespondents (P <
0.001). The only experience group with more respondents than
nonrespondents was physicians with 25 years or more of ID ex
perience (52% response rate [167/324]). No other group had a
response rate higher than 37%. Baseline characteristics of sur
vey respondents are provided in Supplementary Table 1.
There was no difference in survey response between physicians
practicing in endemic regions vs physicians in other areas—
193/519 (37%) vs 358/948 (38%) (P = 0.83).
Endemicity

Survey respondents who reported seeing patients with histo
plasmosis were significantly different from those who did not
based on years of experience and region of practice (Table 1).
In Histoplasma-endemic areas, 82% (158/193) of physicians re
ported seeing patients with histoplasmosis compared to 27%
(95/358) of physicians in areas not considered endemic (P <
0.001). The percentages of physicians who reported seeing his
toplasmosis are presented by geographic region in Figure 1 and
by US state and Canadian province in Supplementary Table 2.
Management of Acute Pulmonary and Progressive Disseminated
Histoplasmosis

For a patient with mild-to-moderate acute pulmonary histo
plasmosis, 75% (189/253) of respondents treat with itracona
zole as is recommended in both the IDSA and the European
Confederation of Medical Mycology guidelines [8, 14]. Six per
cent (16/253) chose treatment with another azole and 4% (9/
253) chose amphotericin B. Forty-seven (19%) respondents
recommended no treatment for the patient in this case.
For a patient presenting with mild-to-moderate disseminat
ed histoplasmosis in the outpatient setting, 75% (189/253) of
respondents chose to treat with itraconazole in concordance
with the guidelines. Fewer respondents recommended no treat
ment in this situation (14% [35/253]) and more recommended
amphotericin B induction therapy (9% [22/253]). The remain
der of respondents chose another azole.
Preferences in Azole Therapy

Most respondents chose itraconazole as their azole of choice in
each clinical scenario. Preferred formulations of itraconazole
were evenly split between oral solution (46% [117/253]) and
capsules (43% [110/253]). A minority of physicians (7% [18/
253]) preferred the newest formulation, SUBA-itraconazole.
There were 6 physicians (2%) who did not treat histoplasmosis
with itraconazole.
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use in treating histoplasmosis [11–13]. Since the arrival of these
new medications, there have been no changes to clinical prac
tice recommendations [14], and very little new data have been
published to guide therapy [15, 16]. Additionally, the popula
tion at risk to develop clinically significant histoplasmosis has
increased substantially with millions of patients on an everexpanding variety of immunosuppressive medications and/or
with immunosuppressive medical conditions [17–19].
Limited data have been added to the histoplasmosis literature
since the last IDSA guidelines were published, though physi
cians have gained an additional 15 years of experience managing
histoplasmosis. The aim of this study was to characterize the
current histoplasmosis management patterns of infectious dis
ease (ID) physicians, identify areas of disagreement, and extract
clinical insights gained from our collective experience.

Table 1. Baseline Characteristics of Survey Respondents Who Do and Do
Not See Patients With Histoplasmosis

See Histoplasmosis
(n = 253)

P
Value

<5

43 (40)

65 (60)

<.001

5–14

90 (50)

92 (50)

15–24

53 (56)

41 (44)

112 (67)

55 (33)

Characteristic
Years of experience

≥25
Primary employment
Hospital/clinic

123 (57)

94 (43)

University/medical
school

86 (50)

87 (50)

Private practice
group

69 (54)

59 (46)

Federal government

18 (60)

12 (40)

2 (67)

1 (33)

Military

.64

111 (54)

94 (46)

Community hospital

84 (58)

60 (42)

Non-university
teaching hospital

69 (51)

66 (49)

City/county hospital

12 (44)

15 (56)

VA hospital or DOD

20 (53)

18 (47)

Outpatient only

2 (100)

.51

0 (0)

Census division of practicea
New England

37 (84)

7 (16)

Mid-Atlantic

66 (79)

18 (21)

East North Centralb

17 (24)

54 (76)

West North Centralb

8 (13)

55 (87)

55 (56)

44 (44)

2 (10)

17 (90)

8 (20)

32 (80)

South Atlantic
East South Centralb
b

West South Central
Mountain

19 (83)

3 (17)

Pacific

81 (79)

21 (21)

Canada

5 (83)

1 (17)

Forty-one percent (105/253) of respondents recommended to
discontinue antifungal treatment after 12 months of therapy
for an immunocompetent patient with disseminated histoplas
mosis and resolution of symptoms but with persistent
Histoplasma antigenuria (>19 ng/mL to 1.1 ng/mL). Twenty
percent (51/253) of respondents chose to extend therapy for
1–12 months and 37% (93/253) recommended continuing
treatment until antigenuria had resolved.
Management of Fibrosing Mediastinitis

Primary hospital setting
University hospital

Discontinuation of Antifungal Therapy in the Setting of Persistent
Antigenuria

<.001

Data are presented as No. (%). Values in bold are statistically significant.
Abbreviations: DOD, US Department of Defense; VA, Veterans Affairs.
a

States in the US Census Bureau divisions are as follows: New England (Maine, New
Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut); Mid-Atlantic
(New York, New Jersey, Pennsylvania); East North Central (Ohio, Indiana, Illinois,
Michigan, Wisconsin); West North Central (Minnesota, Iowa, Missouri, North Dakota,
South Dakota, Nebraska, Kansas); South Atlantic (Delaware, Maryland, District of
Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida); East
South Central (Kentucky, Tennessee, Alabama, Mississippi); West South Central
(Arkansas, Louisiana, Oklahoma, Texas); Mountain (Montana, Idaho, Wyoming, Colorado,
New Mexico, Arizona, Utah, Nevada); Pacific (Washington, Oregon, California, Alaska,
Hawaii).

b

US Census Bureau divisions considered to be traditionally endemic for Histoplasma.

Itraconazole was recommended for step-down therapy for
severe disseminated histoplasmosis without central nervous
system (CNS) involvement by 92% (232/253) of respondents.
Where severe disseminated histoplasmosis was complicated
by CNS involvement, a smaller majority (145/253 [57%]) rec
ommended itraconazole. For CNS involvement, 19% (48/253)
recommended voriconazole, 5% (12/253) posaconazole, 4%
(9/253) isavuconazole, and 8% (20/253) fluconazole.
Continued therapy with amphotericin B was recommended
by 7% (17/253) of respondents.

Consistent with the 2007 guidelines, most respondents (170/
253 [67%]) chose to recommend a stenting procedure for a pa
tient with fibrosing mediastinitis complicated by several epi
sodes of postobstructive pneumonia and new constriction of
a main pulmonary bronchus and superior vena cava. Other op
tions recommended were surgery (111/253 [44%]), steroids
(81/253 [32%]), an azole (37/253 [15%]), amphotericin B (32/
253 [13%]), rituximab (12/253 [5%]), and nonsteroidal antiinflammatory medications (8/253 [3%]). This question allowed
for multiple treatment modalities to be recommended and the
totals add up to >100%.
Management of Histoplasmosis in Immunocompromised Patients

The majority of physicians that reported seeing patients with
histoplasmosis (165/253 [65%]) did not recommend screening
for histoplasmosis prior to patients starting immunosuppres
sion (eg, during pretransplant evaluation, prior to starting bio
logics). This response did not vary by the endemicity of practice
location (P = 0.10).
Survey respondents did not reach a majority consensus for 3
scenarios: restarting immunosuppression after a diagnosis of
disseminated histoplasmosis in a patient with Crohn disease
on adalimumab; recommending lifelong Histoplasma suppres
sion after histoplasmosis treatment in various immunocom
promising conditions; and deciding when to recommend
treatment of an isolated, asymptomatic pulmonary nodule (his
toplasmoma). Responses for these questions are available in
Supplementary Table 3.
The question about lifelong antifungal suppression prompt
ed 30 free-text responses. Nearly all of the responses (29/30
[97%]) commented that a more nuanced approach to recom
mendations was required. Examples include “decision based
on level of ongoing immunosuppression,” “case-by-case risks
vs benefits discussion,” and “highly depends on depth and du
ration of immunosuppression.” Comments about basing rec
ommendations on specific aspects of clinical situations
continued in the last free-text box asking for general comments
Treatment of Histoplasmosis by ID Physicians • OFID • 3
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Do Not See
Histoplasmosis
(n = 298)

Antifungal preferences for these specific clinical scenarios
are presented in Table 2.

about the survey. An additional 22 comments mentioned need
ing additional information in the survey clinical scenarios.
Examples of these responses include: “Some of my answers
would be more nuanced,” “Great questions but some lack suf
ficient data to make a single firm conclusion,” and “Several sce
narios are hard to answer with absolute confidence. There are
perhaps various potential peculiarities to each patient scenario
that might cause me to act differently.”

DISCUSSION

We report survey results for 551 physicians describing manage
ment of histoplasmosis by ID specialists. Less than half of re
spondents indicated that they see patients diagnosed with

histoplasmosis, which limits the strength of conclusions that
may be made from these data. There is a growing number
of reports of locally acquired Histoplasma (ie, without docu
mented travel to an endemic region) in areas not known to
be endemic, with documented cases crossing North America
from Alaska to Florida [22–26]. These cases suggest an evolving
geographic distribution of Histoplasma.
The geographic distribution of Histoplasma was defined in the
1950s with no systematic update since 1969 [27, 28]. These studies
were based on histoplasmin skin testing rather than histoplasmo
sis diagnoses (incidence) or isolation of Histoplasma from envi
ronmental reservoirs. Despite using an indirect measure to
determine geographic distribution, these historical maps have
been the foundation for Histoplasma’s endemic mycosis

Table 2. Infectious Disease Physician Preferences in Antifungal Therapy Based on Clinical Scenario

Clinical Situation

Itraconazole Voriconazole Posaconazole Isavuconazole Fluconazole AmB

No
Treatment

Not
Answered

Mild-moderate acute pulmonary histoplasmosis with
symptoms lasting >1 mo

189 (75)

3 (1)

2 (<1)

0 (0)

2 (<1)

9 (4)

47 (19)

1 (<1)

Mild-moderate progressive disseminated
histoplasmosis (outpatient presentation)

189 (75)

3 (1)

2 (<1)

0 (0)

1 (<1)

22 (9)

35 (14)

1 (<1)

Step-down therapy for disseminated histoplasmosis
without CNS involvement after AmB induction

232 (92)

8 (3)

9 (4)

0 (0)

3 (1)

NA

NA

1 (<1)

Step-down therapy for disseminated histoplasmosis
with CNS involvement after AmB induction

145 (57)

48 (19)

12 (5)

9 (4)

20 (8)

17 (7)

NA

2 (<1)

Data are presented as No. (%) of respondents (n = 253).
Abbreviations: AmB, amphotericin B; CNS central nervous system; NA, not applicable.
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Figure 1. Percentage breakdown of survey respondents reporting seeing patients with histoplasmosis, by United States Census Bureau division.

majority consensus to our survey questions about immunocom
promised patients is a manifestation of the lack of data available
to guide complex management decisions. The free-text commen
taries from our survey expressed a similar sentiment; there is lim
ited literature to guide the management of immunocompromised
patients with histoplasmosis, and updated guideline recommen
dation are needed to address the management of immunocom
promised patients with histoplasmosis.
The 2007 IDSA guideline recommendations were followed
by the majority of respondents in most of the clinical scenarios
in our survey [8]. The importance of the IDSA guidelines was
demonstrated explicitly by survey comments such as “I would
generally refer to published guidelines for every scenario which
the guidelines address” and “I follow the IDSA guidelines al
ways.” A less explicit example of guideline importance is the
majority recommendation for itraconazole as step-down ther
apy for histoplasmosis of the CNS. Though there have been no
head-to-head trials comparing itraconazole to newer azoles,
voriconazole and isavuconazole are known to achieve higher
concentrations in the CNS [39–41]. Better CNS penetration
with antifungal medications with activity against Histoplasma
is an attractive treatment option, though an option recom
mended by a minority of respondents in our survey.
CONCLUSIONS

Histoplasmosis is a challenging infection to manage and there
is a paucity of research to guide management decisions. This re
ality reiterates the need for more investment and research into
fungal pathogens, including Histoplasma. Medical providers
need to adapt to the expanded geographical distribution of
Histoplasma when considering fungal diagnoses. The new
IDSA guidelines must reflect the growing need for general
guidance for histoplasmosis management, particularly in im
munocompromised populations.
Supplementary Data
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classification, persisting with few changes for >50 years. The maps
delineated from these classical studies have been used to train gen
erations of physicians. Efforts to better characterize endemic areas
are limited by the financial impracticality of repeating the histor
ical studies, the lack of histoplasmin availability, and, in the US, by
histoplasmosis only being reportable in 13 states [29, 30]. Several
research groups and the CDC have produced maps with expanded
areas of likely Histoplasma endemicity [6, 24, 26, 31]. The data in
our survey are comprised of ID physicians practicing in North
America, though histoplasmosis has been reported on every con
tinent except Antarctica [6]. Practice patterns in North America
may not be applicable worldwide, though the need for better his
toplasmosis data applies broadly.
Given the data suggesting an expanded geographic distribution
of Histoplasma, it is the recommendation of the authors that his
toplasmosis be broadly considered as a potential diagnosis for a
patient with a compatible clinical syndrome. The amount of sub
sequent consideration given to a histoplasmosis diagnosis can later
be adjusted after accounting for geographic, environmental (eg,
employment as an excavator, spelunking enthusiast), and host
risk factors (eg, immunocompromise). This recommendation is
intended to mitigate diagnostic delay. Another recent EIN survey
found that only 23% of ID physicians “never” or “rarely” observed
a diagnostic delay when treating endemic fungal infections, in
cluding histoplasmosis [32]. The most common reason given for
the diagnostic delay was failure to consider the diagnosis initially
and was found to have a moderate to major impact in 66% of cases
[32]. The majority of survey respondents did not recommend
screening for histoplasmosis prior to the initiation of immuno
compromising medications. The clinical impact of diagnostic de
lays combined with the low cost and minimally invasive nature of
histoplasmosis screening may support consideration of more
common screening in high-risk patients. It is easy to envision
more widespread histoplasmosis screening in appropriate clinical
scenarios, such as cryptococcus and tuberculosis, especially with
additional data to support this practice and the development of
improved diagnostics.
Many clinical conundrums in the management of histoplas
mosis occur in the growing number of immunocompromised
hosts [17]. Management decisions in this population must bal
ance the severity of the histoplasmosis, type and degree of immu
nosuppression, necessity for ongoing immunosuppression (eg,
transplants or rheumatologic conditions), potential for immune
recovery (eg, following myeloablative chemotherapy), and poten
tial interactions of antifungal medications (eg, triazoles with ta
crolimus or antineoplastic agents [33]). There are limited data
addressing these situations. Clinical trial data are often limited
to immunocompromise secondary to human immunodeficiency
virus [34, 35], and guideline recommendations are available spe
cifically for this patient population [36]. The literature addressing
histoplasmosis with other forms of immunocompromise is com
posed of retrospective, observational studies [37, 38]. The lack of
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